Navigation Links
Verinata Health Announces New Findings At The American Society Of Human Genetics

REDWOOD CITY, Calif., Nov. 9, 2012 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today announced two poster presentations at the 62nd Annual Meeting of the American Society of Human Genetics (ASHG). The conference is being held in San Francisco, California.


"The verifi® prenatal test offers pregnant women access to a blood test that is safe, early and accurate," said Dr. Jeffrey Bird, Executive Chairman and CEO of Verinata Health.  "Looking beyond our current product offering, our early work presented at ASHG represents an exciting possibility for future non-invasive prenatal tests. While this initial work serves as a proof of principal, it clearly demonstrates the power and potential of massively parallel sequencing to detect alterations within individual chromosomes, similar to chromosomal microarrays."

The following posters were presented at ASHG on Thursday, November 8, 2012:

  • Detection of Fetal Sub-Chromosomal Alterations in Maternal Plasma Cell-Free DNA (cfDNA) Using Massively Parallel Sequencing (MPS). (Poster #3021T) This poster demonstrates that Verinata's proprietary technology, together with next-generation sequencing, can be used to detect subchromosomal changes in the fetus.
  • cfDNA is not Compromised by Temperature Stress of Maternal Blood Collected in Streck Cell-Free DNA BCT. (Poster #3007T)

About the verifi® prenatal test
The verifi® prenatal test is a blood test that analyzes genetic material (or DNA) naturally found in a pregnant woman's blood to detect the most common fetal chromosome abnormalities.  When directed by a physician, the verifi test can be offered to pregnant women of at least 10 weeks gestation at high risk of carrying a fetus with a genetic abnormality. A physician may classify a woman as "high-risk" if she is over 35 years of age, has a prior personal or family history of chromosome abnormalities, or has had a positive initial screening test indicating she is at increased risk for carrying a fetus with a genetic abnormality.

Verinata Health, Inc.
Verinata is driven by a sole, extraordinary purpose – maternal and fetal health. Our initial focus is to develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities using our proprietary technologies. We aim to reduce the anxiety associated with today's multi-step process, the unacceptable false-positive rates, the non-specific and sometimes confusing results of current prenatal screening methods, as well as the risk of current invasive procedures. In support of national guidelines recommending first trimester aneuploidy risk assessment, we believe women who desire such an assessment should be offered a single blood draw test with a definitive result. The verifi® prenatal test is available throughout the United States, with the exception of New York, through a physician. For more information about Verinata, please go to

SOURCE Verinata Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Genomic Health to Present at Two Upcoming Investor Conferences
2. Baylor University scientist receives major grants for health research on 1991 Gulf War veterans
3. Obese dogs at risk of health condition experienced by humans
4. Obese moms give birth to heart healthier kids following bariatric surgery
5. New Study Shows That Improvements in Employee Health Behaviors Persist Over Two Years
6. US investment in biomedical and health research on downward trend
7. Omega-3 intake heightens working memory in healthy young adults
8. Pigs look healthy but test positive for flu at fairs; transmission seen between pigs and humans
9. INTEGRIS Health Puts Patient Safety in the Palm of Your Hand
10. Study: DNA barcoding can ID natural health products
11. App lets you monitor lung health using only a smartphone
Post Your Comments:
(Date:11/9/2015)... 09, 2015 ... the "Global Law Enforcement Biometrics Market ... --> ) has announced the ... Biometrics Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:10/29/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that it has been ... one of only three finalists for a 2015 ... Growing" category. The Tekne Awards honor Minnesota ... innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... --> --> ... by Transparency Market Research, the global non-invasive prenatal testing ... 17.5% during the period between 2014 and 2022. The ... Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... to reach a valuation of US$2.38 bn by 2022. ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh industrial ... points for in-line sensors can represent a weak spot where leaking process media ... of retractable sensor housings , which are designed to tolerate extreme process conditions. ...
(Date:11/24/2015)... LOS ANGELES , Nov. 24, 2015 ... a biotechnology company focused on the discovery, development and ... Marban , Ph.D., Chief Executive Officer, is scheduled to ... December 1, 2015 at 10:50 a.m. EST, at The ... York City . . ...
(Date:11/24/2015)... ... , ... Whitehouse Laboratories is pleased to announce that it has completed construction ... dedicated to basic USP 61, USP 62 and USP 51 testing specific to raw ... and micro testing performed by one supplier. Management has formally announced that ...
Breaking Biology Technology: